Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $243.00 by Analysts at Needham & Company LLC

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price dropped by analysts at Needham & Company LLC from $357.00 to $243.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC‘s target price points to a potential upside of 39.66% from the stock’s current price.

A number of other research analysts have also recently issued reports on ALNY. Wells Fargo & Company cut their price target on Alnylam Pharmaceuticals from $256.00 to $253.00 and set an “equal weight” rating for the company in a report on Wednesday, October 14th. Oppenheimer lowered their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Bank of America lowered their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Stifel Nicolaus downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 target price for the company. in a research note on Thursday. Finally, Zacks Research lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $355.10.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $58.40 during midday trading on Thursday, reaching $174.00. 11,798,480 shares of the company’s stock traded hands, compared to its average volume of 1,493,059. The company has a 50-day simple moving average of $239.15 and a two-hundred day simple moving average of $288.34. Alnylam Pharmaceuticals has a 1-year low of $172.31 and a 1-year high of $479.79. The company has a market cap of $23.28 billion, a price-to-earnings ratio of 32.34 and a beta of 0.28. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.90 earnings per share. On average, analysts anticipate that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Traynor Capital Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 22.6% in the 3rd quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company’s stock valued at $3,163,000 after acquiring an additional 2,360 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $18,226,000. Profund Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 22.5% in the 3rd quarter. Profund Advisors LLC now owns 16,919 shares of the biopharmaceutical company’s stock valued at $4,175,000 after acquiring an additional 3,105 shares during the period. ProShare Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 4.2% in the 3rd quarter. ProShare Advisors LLC now owns 133,935 shares of the biopharmaceutical company’s stock valued at $33,047,000 after acquiring an additional 5,421 shares during the period. Finally, Vise Technologies Inc. increased its stake in Alnylam Pharmaceuticals by 67.4% in the third quarter. Vise Technologies Inc. now owns 2,079 shares of the biopharmaceutical company’s stock valued at $513,000 after purchasing an additional 837 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up 16.7% year over year and ahead of analyst expectations. Earnings of $16.26 per share also exceeded estimates by a wide margin. Alnylam Pharmaceuticals Reports Third-Quarter Earnings Results
• Positive Sentiment: The company reaffirmed its fiscal 2026 net product-sales outlook, providing some reassurance that management continues to expect solid commercial performance. Alnylam Fiscal 2026 Outlook
• Positive Sentiment: Alnylam expanded its Phase 3 nucresiran heart-disease trial while citing a high level of conviction in the program. It also highlighted continued progress across its RNA interference pipeline. Alnylam Revenue Growth and Pipeline Update
• Neutral Sentiment: The exceptionally high EPS result was helped by an approximately $1.9 billion tax benefit, making the headline earnings beat less representative of recurring operating performance. Alnylam Third-Quarter Tax Windfall
• Negative Sentiment: Shares fell even after the earnings beat as investors reacted to slower growth in U.S. Amvuttra and Onpattro sales, raising concerns about the pace of the commercial business. Alnylam Sales Growth Concerns
• Negative Sentiment: Expanding the nucresiran trial may increase development costs and extend the timeline before investors receive definitive clinical results, despite management’s confidence in the drug. Alnylam Nucresiran Study Update
• Negative Sentiment: Stifel Nicolaus downgraded ALNY from “buy” to “hold,” reflecting a more cautious view of the shares’ near-term risk-reward profile, even though its $225 price target remains above the current level.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.